These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21047040)

  • 1. The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study.
    Jackson K; Ashby M; Howell D; Petersen J; Brumley D; Good P; Pisasale M; Wein S; Woodruff R
    J Palliat Care; 2010; 26(3):176-83. PubMed ID: 21047040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care.
    Salas S; Frasca M; Planchet-Barraud B; Burucoa B; Pascal M; Lapiana JM; Hermet R; Castany C; Ravallec F; Loundou A; Auquier P; Duffaud F; Baumstarck K
    J Palliat Med; 2012 Mar; 15(3):287-93. PubMed ID: 22335487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain.
    Hardy J; Quinn S; Fazekas B; Plummer J; Eckermann S; Agar M; Spruyt O; Rowett D; Currow DC
    J Clin Oncol; 2012 Oct; 30(29):3611-7. PubMed ID: 22965960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
    Jackson K; Ashby M; Martin P; Pisasale M; Brumley D; Hayes B
    J Pain Symptom Manage; 2001 Oct; 22(4):834-42. PubMed ID: 11576800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subanesthetic, Subcutaneous Ketamine Infusion Therapy in the Treatment of Chronic Nonmalignant Pain.
    Zekry O; Gibson SB; Aggarwal A
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):91-8. PubMed ID: 27092576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis.
    Patil S; Anitescu M
    Pain Med; 2012 Feb; 13(2):263-9. PubMed ID: 21939497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine for Refractory Headache: A Retrospective Analysis.
    Schwenk ES; Dayan AC; Rangavajjula A; Torjman MC; Hernandez MG; Lauritsen CG; Silberstein SD; Young W; Viscusi ER
    Reg Anesth Pain Med; 2018 Nov; 43(8):875-879. PubMed ID: 29923953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain.
    Amin P; Roeland E; Atayee R
    J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):233-42. PubMed ID: 25102039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
    Tsui BC; Davies D; Desai S; Malherbe S
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):678-80. PubMed ID: 15454842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit.
    Fitzgibbon EJ; Viola R
    J Palliat Med; 2005 Feb; 8(1):49-57. PubMed ID: 15662173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of ketamine for intractable cancer pain.
    Lossignol DA; Obiols-Portis M; Body JJ
    Support Care Cancer; 2005 Mar; 13(3):188-93. PubMed ID: 15480820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer?
    Okamoto Y; Tsuneto S; Tanimukai H; Matsuda Y; Ohno Y; Tsugane M; Uejima E
    Am J Hosp Palliat Care; 2013 Aug; 30(5):450-4. PubMed ID: 22833552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subanesthetic ketamine for cancer pain: by insisting on level I/II evidence, do we risk throwing the baby out with the bath water?
    Jackson K; Ashby M; Goodchild C
    J Pain Symptom Manage; 2005 Apr; 29(4):328-30. PubMed ID: 15857732
    [No Abstract]   [Full Text] [Related]  

  • 14. Opioid-sparing effect of intravenous outpatient ketamine infusions appears short-lived in chronic-pain patients with high opioid requirements.
    Kapural L; Kapural M; Bensitel T; Sessler DI
    Pain Physician; 2010; 13(4):389-94. PubMed ID: 20648208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
    Finkel JC; Pestieau SR; Quezado ZM
    J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome.
    Correll GE; Maleki J; Gracely EJ; Muir JJ; Harbut RE
    Pain Med; 2004 Sep; 5(3):263-75. PubMed ID: 15367304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo-controlled trial.
    Vranken JH; Dijkgraaf MG; Kruis MR; van Dasselaar NT; van der Vegt MH
    Pain; 2005 Nov; 118(1-2):224-31. PubMed ID: 16202531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain.
    Kajiume T; Sera Y; Nakanuno R; Ogura T; Karakawa S; Kobayakawa M; Taguchi S; Oshita K; Kawaguchi H; Sato T; Kobayashi M
    J Palliat Med; 2012 Jun; 15(6):719-22. PubMed ID: 22401313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio.
    Benítez-Rosario MA; Salinas-Martín A; González-Guillermo T; Feria M
    J Pain Symptom Manage; 2011 Jun; 41(6):1098-105. PubMed ID: 21398087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.